Latest Weight-Loss Drug , Faces Shortages .
The United States Food and Drug Administration (FDA) says that high demand has left the latest weight-loss drug, Zepbound, in short supply.
'Newsweek' reports that the Eli Lilly product is expected to experience limited availability through Q2 of 2024 as surging demand has outpaced the manufacturer's expectations.
We have experienced an unparalleled surge in demand for our type 2 diabetes and obesity medicines, Eli Lilly spokesperson, via 'Newsweek'.
We recognize this situation may cause a disruption in peoples' treatment regimens and are working with purpose and urgency to help meet the surge in demand, Eli Lilly spokesperson, via 'Newsweek'.
The FDA said that Novo Nordisk's weight-loss drug, Wegovy, is also experiencing a widespread supply shortage with no end in sight for the drug's limited availability.
By the year 2030, 'Newsweek' reports that the weight-loss drug market is expected to grow to about $100 billion.
We expect our investments in manufacturing and supply capacity to progressively increase production of our medicines throughout 2024 and beyond, Eli Lilly spokesperson, via 'Newsweek'.
Over the past year, manufacturer Eli Lilly has already seen share prices rise over 102%.
The company has announced plans to expand operations to meet increased demand for its incretin products which are used in the firm's diabetes treatments.
.
Incretin mimics gut hormones that regulate blood sugar while also suppressing appetite
